Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Restructuring Costs (2024)

Amylyx Pharmaceuticals has reported Restructuring Costs over the past 1 years, most recently at $22.9 million for Q2 2024.

  • Quarterly results put Restructuring Costs at $22.9 million for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2025 was $22.9 million (changed N/A YoY), and the annual figure for FY2024 was $22.9 million, changed.
  • Restructuring Costs for Q2 2024 was $22.9 million at Amylyx Pharmaceuticals.
  • Over the last five years, Restructuring Costs for AMLX hit a ceiling of $22.9 million in Q2 2024 and a floor of $22.9 million in Q2 2024.